Publications

2017

1. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. J O'Connor, MJ Vjecha, AN Phillips, B Angus, D Cooper, B Grinsztejn, G Lopardo, S Das, R Wood, A Wilkin, H Klinker, P Kantipong, KL Klingman, D Jilich, E Herieka, E Denning, I Abubakar, F Gordin, JD Lundgren; INSIGHT START study group.
Lancet HIV. 2017, 4(3) e105-e112. Abstract

2 Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
P Ljungman, M Boeckh, HH Hirsch, F Josephson, J Lundgren, G Nichols, A Pikis, RR Razonable, V Miller, PD Griffiths; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum.
Clin Infect Dis. 2017 ;64(1):87-91. Epub 2016 Sep 28.Abstract

An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings. 
F Nakagawa, V Delpech, J Albert, A Alioum, D Bezemer, M Cortina-Borja, AE Brown, V Cambiano, C Campbell, D Costagliola, A de Luca, R Kouyos, R Lodwick, JD Lundgren, N Pantazis, C Smith, V Supervie, P Tookey, G Touloumi, Zh Yin, A van Sighem, AN Phillips
AIDS. 2017 ;31(3):417-425. Abstract

4 One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. D.N. Podlekareva, A. Schultze, A. Panteleev, A.M. Skrahina, J.M. Miro,  A. Rakhmanova, H. Furrer, R.F Miller, A.M. W. Efsen, M.H. Losso, J. Toibaro, A. Vassilenko, E. Girardi, J.D. Lundgren, A. Mocroft, F.A. Post, O. Kirk, on behalf of the TB:HIV study group in EuroCoord.
AIDS. 2017;31(3):375-384. abstract

The clinical utility of PDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. NE Wareham, JD Lundgren, C Da Cuncha-Bang, F Gustafsson, M Iversen, HH Johannesen, A Kjær, A Rasmussen, H Sengeløv, SS Sørensen, BM Fischer.
Eur J Nucl Med Mol Imaging. 2017. Abstract

6 Combination antiretroviral therapy and cancer risk. AH Borges
Current opinion in HIV & AIDS 2017, Vol 11 (6) iv-iv 545-627. Abstract

7 Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. AH Borges,J Hoy, E Florence, D Sedlacek, HJ Stellbrink, V Uzdaviniene, J Tomazic, P Gargalianos-Kakolyris, P Schmid, C Orkin, C Pedersen, C Leen, C Pradier, F Mulcahy, AL Ridolfo, T Staub, F Maltez, R Weber, L Flamholc, G Kyselyova JD Lungren, A Mocroft; for EuroSIDA.
Clin Infect Dis 2017. Abstract

8 Late presentation of chronic viral hepatitis for medical care: a consensus definition. S Mauss, S Pol, M Buti , E Duffell, C Gore, JV Lazarus ,HL  der Grient, J Lundgren, A Mozalevskis, D Raben, E Schatz, S Wiktor, JK Rockstroh; European consensus working group on late presentation for Viral Hepatitis Care.
BMC Medicine 2017; 15(1):92 abstract

9 Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. TS Itenov, JU Jensen, SR Ostrowski, PI Johansson, KM Thormar, JD Lundgren, MH Bestle; “Procalcitonin And Survival Study” study group.
Shock 2017, 47(6) 696-701. Abstract

10 Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. JV Baker, S Sharma, AC Achhra, JI Bernardino, JR Bogner,  D Duprez, S Emery, B Gazzard, J Gordin, G Grandits, AN Phillips, S Schwarze, EZ Soliman, SA Spector, G Tambussi, J Lundgren; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.
Journal of the American Heart Association 2017; 6(5). Abstract 

11 Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. E Lord, AJ Stockdale, R Malek, C Rae, I Sperle, D Raben, A Freedman, D Churchill, J Lundgren, AK Sullivan; British Association of Sexual Health HIV (BASHH)/British HIV Association (BHIVA) guideline review group for the Optimising Testing and Linkage to Care for HIV across Europe (OptTEST) project by HIV in Europeb.
HIV Medicine 2017; 18(4): 300-304. Abstract

12. Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. A Cortes, CA Dendrou, A Motyer, L Jostins, D Vukcevic, A Dilthey,P Donnelly, S Leslie, L Fugger, G McVean.
Nat Genet. 2017;49(9):1311-1318. Abstract

13. Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable?
C Ekenberg, IP Lodding, NE Wareham, SS Sørensen, H Sengeløv, F Gustafsson, A Rasmussen, M Perch, JD Lundgren, M Helleberg
Eur J Clin Microbiol Infect Dis. 2017. [Epub ahead of print] Abstract

14. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report. JD Kowalska, C Oprea, S de Witt,  A Pozniak , D Gökengin, M Youle, JD Lundgren, A Horban, & ECEE Network Group
HIV Medicine 2017:18(5): 370-375 Abstract

15. Incidental lung cancers and positive computed tomography images in people living with HIV. A Ronit, T Kristensen, DM Klitbo, M Gelpi, A Kalhauge, T Benfield, J Gerstoft, J Lundgren, J Vestbo, KF Kofoed, SD Nielsen  
AIDS 2017; 31(14): 1973-1977. Abstract

16.  Plasma HIV-1 Tropism and the Risk of Short-Term Clinical Progression to AIDS or Death. M Casadellà, A Cozzi-Lepri, A Phillips, M Noguera-Julian, M Bickel, D Sedlacek, K Zilmer, B Clotet, JD Lundgren, R Paredes. EuroSIDA in EuroCOORD  
PLoSOne 2017; 12(1). Abstract

17. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.  LR Nielsen, A Mocroft, O Kirk, P Reiss, M Ross, C Smith, O Moranne, P Morlat, CA Fux, C Sabin, A Phillips, M Law, JD Lundgren. & D:A:D study group
AIDS 2017 Abstract

18. Small airway dysfunction in well-treated never-smoking HIV-infected individuals A Ronit, IH Mathiesen, M Gelpi, T Benfield, J Gerstoft, T Pressler, A Christiansen, J Lundgren, J Vestbo, S Dam Nielsen.
European Respiratory Journal 2017; 49(3):1602186. Abstract

19. The association between detected drug resistance mutations and CD4(+) T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.
A Schultze, R Paredes, C Sabin, AN Phillips, D Pillay, N Mackie, A Castagna, D Chadwick, K Falconer, AM Geretti, FA Post, T Hill, O Kirk, A Pozniak, MJ Nelson, A Tostevin, D Dunn, J Lundgren, A Cozzi-Lepri
Antiviral therapy 2017. Abstract

20. Forced fluid removal versus usual care in intensive care patients with high-risk acute kidney injury and severe fluid overload (FFAKI): study protocol for a randomised controlled pilot tria
l.  RE Berthelsen, T Itenov, A Perner, JU Jensen, M Ibsen, AEK Jensen, M Bestle
Trials. 2017 ;18(1):189. Abstract

21. Sepsis – frontiers in resuscitation and infection control. A Perner, AC Gordon, D de Backer, G Dimopoulos, JA Russell, J Lipman, JU Jensen, J Myburgh, M Singer, R Bellomo, T Walsh. 
Intensive Care Medicine 2016;42(12):1958-1969. Abstract 

 

2016

  1. Antiretroviral drugs and risk of chronic ALT elevation in HIV-infected persons without viral hepatitis coinfection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, F Dabis, A d’Arminio Monforte, C Smith, S de Wit, O Kirk, JD Lundgren, R Weber , on behalf of the D:A:D Study group. 
    Open Forum Infect Dis. 2016 ;3(1):ofw009. Abstract

  2. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. A Mocroft, JD Lundgren, M Ross, CA Fux  P Reiss, O Moranne, P Morlat, A d'Arminio Monforte, O Kirk, L Ryom, on behalf of The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. 
    Lancet HIV. 2016 ;3(1):e23-32. Abstract

  3. Tuberculosis-related mortality in people living with HIV In Europe and Latin America: an international cohort study. Daria Podlekareva, Anne Marie W. Efsen, Anna Schultze, Frank Post,, Alena M. Skrahina, Alexander Panteleev, Hansjakob Furrer, Robert F. Miller, Marcelo H. Losso, Javier Toibaro, Jose M. Miro, Anna Vassilenko, Enrico Girardi, Mathias Bruyans, Niels Obel, Jens D. Lundgren, Amanda Mocroft, Ole kirk on behalf of the TB:HIV study group in EuroCoord. 
    Lancet HIV. 2016 ;3(3):e120-31. abstract

  4. Identifying key drivers of the impact of an HIV cure intervention in sub-Saharan Africa. A Phillips A, Cambiano, P Revill , F Nakagawa, J Lundgren, L Bansi-Matharu, T Mabugu, M Sculpher, G Garnett, S Staprans, S Becker, J Murungu, SR Lewin, SG Deeks, T Hallett T.*
    J Infect Dis. 2016. 214(1) 73-9. Abstract

  5. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. AH Borges, A Lundh, B Tendal, JA Bartlett, N Clumeck, D Costagliola,ES Daar, P Echeverría, M Gisslén, TB Huedo-Medina, MD Hughes, K Huppler Hullsiek, P Khabo, S Komati, P Kumar, S Lockman, RD MacArthur, F Maggiolo, A Matteelli, JM Miro, S Oka, K Petoumenos, RL Puls, SA Riddler, PE Sax, J Sierra-Madero, C Torti, JD Lundgren.
    Clin Infect Dis. 2016. 63(2) 268-280.  Abstract

  6. IL-6 is a stronger predictor of clinical events than hsCRP or D-dimer during HIV infection. AH Borges,JL O'Connor, AN Phillips, JD Neaton, B Grund, J Neuhaus, MJ Vjecha, A Calmy, KK Koelsch, JD Lundgren; INSIGHT SMART ESPRIT Study Groups.
    J Infect Dis. 2016. 214(3) 408-416 . Abstract 

  7. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d´arminio Monforte; Andrew Phillips; Rainer Weber;  Jens Lundgren;  Matthew G Law; The D:A:D Study Group.
    HIV Med. 2016 (4):255-68.. abstract

  8. MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year. AA Rostved, JD Lundgren, J Hillingsø , L Peters, A Mocroft, A Rasmussen.
    Scand J Gastroenterol. 2016, 51 (11), 1360-1366. Abstract

  9. Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals? DC Boettinger, CA Sabine, A grulich, L Ryom, F Bonnet, P Reiss, A d'Arminio Monforte, O Kirk, A Phillips, M Bower, G Fätkenheuer, JD Lundgren, M Law. On behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group
    AIDS. 2016 ;30(10):1629-37. Abstract 

  10. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. AH Borges, J Neuhaus, AG Babiker, K Henry, MK Jain, A Palfreeman, P Mugyenyi, P Domingo, C Hoffmann, TR Read, S Pujari, M Meulbroek, M Johnson, T Wilkin, R Mitsuyasu. INSIGHT START study Group
    Clin Infect Dis 2016.63(12) 1668-1676. Abstracts

  11. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. Gjærde LI, Shepherd L Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, Braun D, Martel-Laferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L. 
    Clin Infect Dis. 2016 ;63(6):821-9. abstract

  12. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. L Ryom, JD  Lundgren, M Ross, O  Kirk, M  Law, P Morlat, C Smit, E Fontas, CA  Fux, CI  Hatleberg, S de Wit, CA Sabin and A Mocroft for the D:A:D Study Group
    J Infect Dis. 2016 ;214(8):1212-20. abstract

  13. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral TherapyAJ. Rodger V Cambiano, T Bruun, P Vernazza, S Collins; J van Lunzen, GM Corbelli; V Estrada, AM Geretti, A Beloukas, D Asboe, P Viciana, F Gutiérrez, B Clotet, C Pradier, J Gerstoft, R Weber, K Westling, G Wandeler, JM. Prins,  A  Rieger, M Stoeckle, T Kümmerle, T Bini,  A Ammassari, R Gilson, I Krznaric,M Ristola, R Zangerle, P Handberg, A Antela, S Allan,  A N. Phillips, J Lundgren, for the PARTNER Study Group 
    JAMA. 2016;316(2):171-181. Abstract

  14. Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey.  JV Lazarus, K Laut, K Safreed-Harmon, L Peters, M Johnson, G Fätkenheuer, I Khromova, L Vandekerckhove, K Maciejewska, R Radoi, AL Ridolfo, A Mocroft, on behalf of EuroSIDA in EuroCoord. 
    BMC Infectious Diseases 2016 16:335. 
    article

  15.  Associations between HIV-RNA-based indicators and virological and clinical outcomes. K Laut, L Shepherd, C Pedersen, JK Rockstroh, H Sambatakou, D Paduta, R Matulionyte, T Smiatacz, F Mulcahy, JD Lundgren, A Mocroft, O Kirk, on behalf of EuroSIDA in EuroCoord.
    AIDS 2016;30(12):1961-72. 
    abstract

  16. Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. JS Jensen, TS Itenov, KM Thormar, L Hein ,TT Mohr, MH Andersen, J Løken, H Tousi, B Lundgren, HC Boesen, ME Johansen, SR Ostrowski, PI Johansson, J Grarup, J Vestbo, JD Lundgren; Procalcitonin And Survival Study (PASS) Group.
     Ann Intensive Care. 2016 ;6(1):114. Abstract

  17. Improvements over time in short-term mortality following myocardial infarctions in HIV-positive individuals. CI Hatleberg, L Ryom, W El-Sadr, C Smith, R Weber, P Reiss, E Fontas, F Dabis, M Law, A d'Arminio Monforte, S de Wit, A Mocroft, A Phillips, JD Lundgren, C Sabin. On behalf of the D:A:D Study Group.
    AIDS 2016, 30:1583-1596. Abstract 

  18. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: a prospective cohort study JM Llibre, A Cozzi-Lepri, C Pedersen, M Ristola, M Losso, A Mocroft, V Mitsura, K Falconer, F Maltez, M Beniowski, V Vullo, G Hassoun, E Kuzovatova, J Szlavik, A Kuznetsova, H-J Stellbrink, C Duvivier, S Edwards, K Laut, R Paredes for the EuroSIDA Study Group. 
    Medicine 2016, Volume 95(40),  abstract

  19. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. S Lodi, S Sharma, JD Lundgren, AN Phillips, SR Cole, R Logan, BK Agan, A Babiker, H Klinker, H Chu, M Law, JD Neaton, MA Hernán, INSIGHT Strategic Timing of Antiretroviral Treatment (START) study group.
    AIDS 2016, 30(17) 2659-2663. Abstract 

  20. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. KM Kunisaki, DE Niewoehner, G Collins, B Aagaard, NB Atako, E Bakowska, A Clarke, GM Corbelli, E Ekong, S Emery, EB Finley, E Florence, RM Infante, CM Kityo, JS Madero, DE Nixon, E Tedaldi, J Vestbo, R Wood, JE Connett; INSIGHT START Pulmonary Substudy Group.
    Lancet Respir Med. 2016, 4(12) 980-989. Abstract

 

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D StudyA Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, C A. Fux, O Moranne, P Morlat, MA Johnson, L Ryom, D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups 
    PLoS Med 2015, 12 (3)


  2. Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections, IP Lodding, H Sengeløv, C da Cunha-Bang, M Iversen, A Rasmussen, F Gustafsson, JG Downing, J Grarup, N Kirkeby, CM Frederiksen, A Mocroft, SS Sørensen, JD Lundgren,
    On behalf of the MATCH Programme Study Group
    EBioMedicine; 2015 Vol 2, Issue 7 p.669-705


  3. Factors Associated with Plasma IL-6 Levels During HIV Infection,  ÁH Borges, JL O'Connor, AN Phillips, FF Rönsholt, S Pett, MJ Vjecha, MA French, JD Lundgren, INSIGHT, SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee
    J Infect Dis. 2015. 212, 585- 595


  4. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, The INSIGHT START Study Group, JD Lundgren, AG Babiker , F Gordin, S Emery, B Grund, S Sharma, A Avihingsanon, DA Cooper, G Fätkenheuer, JM Llibre, J Molina, P Munderi, M Schechter, R Wood, KL Klingman, S Collins, HC Lane, AN Phillips, JD Neaton, The INSIGHT START Study Group 
    New England J Med 2015, 373: 795-807 

  5. Late presentation for HIV care across Europe: Update from the collaboration of observational HIV epidemiological research Europe (COHERE) Study 2010 to 2013, The late presenters working group in COHERE in EuroCoord,  A Mocroft et. al.
    Eurosurveillance 2015 Vol 20, Issue 47

  6. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P. 
    Nature. 2015 ;528(7580):S68-76.